{"success":true,"data":{"pressRelease":{"id":"96078","rtpr_id":"nBw1zClqpa","ticker":"ALIKO","exchange":"Euronext Paris","all_tickers":["ALIKO"],"title":"Aliko Scientific: Hospitex International Signs First Agreement With the Uzbek Oncology Institute for the Feasibility Study of a National Urine24 Screening Project","author":"Business Wire","published_at":"2026-07-23T05:30:00.109Z","article_body":"Aliko Scientific: Hospitex International Signs First Agreement With the Uzbek\nOncology Institute for the Feasibility Study of a National Urine24 Screening\nProject\n\n\n * Confirmation of the growing international interest in Urine24 and significant\nrecognition of Aliko Scientific’s expertise in large-scale oncological\ndiagnostic solutions\n\n * Immediate launch of a comprehensive feasibility study covering the technical,\noperational, regulatory, financial and organizational aspects of the future\nprogramme\n\n * An initial phase of potential implementation estimated at approximately €1\nmillion, subject to positive conclusions from the study and the completion of\nthe required procedures\n\nRegulatory News:\n\nAliko Scientific SA (former Ikonisys SA - Euronext Growth Paris: ALIKO) –\ntoday announced that its wholly-owned Italian subsidiary, Hospitex\nInternational S.r.l., has signed a first agreement with the Jizzakh branch of\nthe Republican Scientific and Practical Centre specialising in oncology and\nradiology in Djizak, Uzbekistan.\n\nFrancesco Trisolini, Managing Director of Hospitex International, said:\n“This first agreement confirms the growing international interest in Urine24\nand represents a significant recognition of Aliko Scientific’s expertise in\nthe field of large-scale oncological diagnostic solutions. The decision by the\nUzbek Institute of Oncology to draw on our expertise to explore a national\nscreening programme represents a significant step in the Group’s strategy to\ndevelop, in international markets, accessible cancer diagnostic solutions\nbased on the Urine24 technological model.”\n\nUnder this agreement, the Uzbek Institute of Oncology has decided to draw on\nHospitex International’s expertise to carry out a feasibility study for a\npotential urinary tract cancer screening programme based on the Urine24 model,\nwhich could be rolled out on a national scale.\n\nThe agreement on which work has already begun, covers a feasibility study\naimed at assessing the technical, operational, regulatory, financial and\norganisational conditions necessary for the potential launch of a pilot\nscreening programme in the country.\n\nThe study will include operational workflow definition, laboratory and\nlogistics assessment, legal and regulatory review, financial modelling,\nfunding-strategy analysis and an in-country mission by Hospitex\nrepresentatives. At the end of the assignment, Hospitex will deliver an\nOperational Project Document intended to support institutional review and the\npotential structuring of the next phase.\n\nSubject to the positive outcome of the feasibility study and to the completion\nof the required institutional and contractual steps, the parties plan to\nevaluate a first implementation phase for an estimated value of approximately\n€1 million.\n\nUrine24 is the screening model developed by Hospitex International to\nfacilitate the early detection of urinary tract cancers through a modular and\nscalable pathway, adapted for deployment in healthcare systems with varying\nlevels of infrastructure and diagnostic capabilities.\n\nThis collaboration follows an institutional visit to Hospitex’s\nheadquarters, organised as part of the Health Study Tour promoted by the\nItalian Trade Agency (ICE), with the participation of healthcare delegations\nfrom Asian countries.\n\n-----------------------\n\nAbout ALIKO SCIENTIFIC (Ikonisys SA)\n\nHeadquartered in Paris, ALIKO SCIENTIFIC is the parent company of an\ninternational ecosystem of businesses dedicated to advancing oncology\ndiagnostics. Listed on Euronext Growth Paris under the ticker ALIKO, the\ncompany coordinates industrial, financial and research activities through its\nsubsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO\nSCIENTIFIC’s mission is to innovate cancer diagnosis by uniting cutting-edge\ntechnologies, resources, and strategic investments to create a global center\nof excellence in oncology.\n\nFor more information, visit: www.alikoscientific.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.alikoscientific.com&esheet=54575220&newsitemid=20260722811359&lan=en-US&anchor=www.alikoscientific.com&index=1&md5=0f3c61886e4a9cf439a11f51dec92bd0)\n\nAbout IKONISYS\n\nIkonisys is a global leader in automated diagnostics, specializing in\nfluorescence in situ hybridization (FISH) and circulating tumor cell (CTC)\ndetection. Leveraging advanced artificial intelligence (AI) and a fully\nautomated microscopy platform, Ikonisys provides unmatched precision,\nscalability, and efficiency in cancer diagnostics and treatment monitoring.\nRecognized as pioneer in automation for rare cell detection, Ikonisys is at\nthe forefront of personalized medicine, empowering clinicians to deliver\ntargeted therapies and improve patient outcomes.\n\nFor more information, visit: www.ikonisys.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fikonisys.com%2F&esheet=54575220&newsitemid=20260722811359&lan=en-US&anchor=www.ikonisys.com&index=2&md5=35c137c826f1f496dbf1772bf32381ee)\n\nAbout HOSPITEX\n\nHospitex, based in Florence, Italy, is a global leader in cytology innovation.\nThe company conducts in-house research, development, and production, thus\nensuring the highest standards of quality. Hospitex offers the world’s most\nadvanced Liquid-Based Cytology (LBC) technology, capable of processing any\ncytological sample with unmatched precision. Hospitex is uniquely positioned\nas the only company fully prepared for seamless digital integration, paving\nthe way for a transformative future in cytology diagnostics.\n\nFor more information, visit: www.hospitex.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhospitex.com%2F&esheet=54575220&newsitemid=20260722811359&lan=en-US&anchor=www.hospitex.com&index=3&md5=c73f921d73f84be951e719dffcad708b)\n\nDisclaimer\n\nThis press release contains forward-looking statements about the Company’s\nprospects and development. These statements are sometimes identified by the\nuse of the future tense, the conditional tense and forward-looking words such\nas “believe”, “aim to”, “expect”, “intend”, “estimate”,\n“believe”, “should”, “could”, “would” or “will” or, where\nappropriate, the negative of these terms or any other similar variants or\nexpressions. This information is not historical data and should not be\nconstrued as a guarantee that the facts and data set forth will occur. This\ninformation is based on data, assumptions and estimates considered reasonable\nby the Company. It is subject to change or modification due to uncertainties\nrelating to the economic, financial, competitive and regulatory environment.\nThis information contains data relating to the Company’s intentions,\nestimates and objectives concerning, in particular, the market, strategy,\ngrowth, results, financial situation and cash flow of the Company. The\nforward-looking information contained in this press release is made only as of\nthe date of this press release. The Company does not undertake to update any\nforward-looking information contained in this press release, except as\nrequired by applicable law or regulation. The Company operates in a\ncompetitive and rapidly changing environment and therefore cannot anticipate\nall of the risks, uncertainties or other factors that may affect its business,\ntheir potential impact on its business or the extent to which the\nmaterialization of any one risk or combination of risks could cause results to\ndiffer materially from those expressed in any forward-looking information, it\nbeing recalled that none of this forward-looking information constitutes a\nguarantee of actual results.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260722811359/en/\n(https://www.businesswire.com/news/home/20260722811359/en/)\n\nIkonisys \n\nAlessandro Mauri\n\nCFO\n\ninvestors@ikonisys.com (mailto:investors@ikonisys.com)\n\nNewCap \n\nLouis-Victor Delouvrier/Alexandre Massias\n\nInvestor Relations\n\nIkonisys@newcap.eu \n(mailto:ikonisys@newcap.eu) \nTel.: +33 (0)1 44 71 94 94\n\nNewCap \n\nNicolas Mérigeau\n\nMedia Relations\n\nIkonisys@newcap.eu \n(mailto:ikonisys@newcap.eu) \nTel.: +33 (0)1 44 71 94 98\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw1zClqpa","title":"Aliko Scientific: Hospitex International Signs First Agreement With the Uzbek Oncology Institute for the Feasibility Study of a National Urine24 Screening Project","author":"Business Wire","ticker":"ALIKO","created":"2026-07-23T05:30:00.109Z","tickers":["ALIKO"],"exchange":"Euronext Paris","article_body":"Aliko Scientific: Hospitex International Signs First Agreement With the Uzbek\nOncology Institute for the Feasibility Study of a National Urine24 Screening\nProject\n\n\n * Confirmation of the growing international interest in Urine24 and significant\nrecognition of Aliko Scientific’s expertise in large-scale oncological\ndiagnostic solutions\n\n * Immediate launch of a comprehensive feasibility study covering the technical,\noperational, regulatory, financial and organizational aspects of the future\nprogramme\n\n * An initial phase of potential implementation estimated at approximately €1\nmillion, subject to positive conclusions from the study and the completion of\nthe required procedures\n\nRegulatory News:\n\nAliko Scientific SA (former Ikonisys SA - Euronext Growth Paris: ALIKO) –\ntoday announced that its wholly-owned Italian subsidiary, Hospitex\nInternational S.r.l., has signed a first agreement with the Jizzakh branch of\nthe Republican Scientific and Practical Centre specialising in oncology and\nradiology in Djizak, Uzbekistan.\n\nFrancesco Trisolini, Managing Director of Hospitex International, said:\n“This first agreement confirms the growing international interest in Urine24\nand represents a significant recognition of Aliko Scientific’s expertise in\nthe field of large-scale oncological diagnostic solutions. The decision by the\nUzbek Institute of Oncology to draw on our expertise to explore a national\nscreening programme represents a significant step in the Group’s strategy to\ndevelop, in international markets, accessible cancer diagnostic solutions\nbased on the Urine24 technological model.”\n\nUnder this agreement, the Uzbek Institute of Oncology has decided to draw on\nHospitex International’s expertise to carry out a feasibility study for a\npotential urinary tract cancer screening programme based on the Urine24 model,\nwhich could be rolled out on a national scale.\n\nThe agreement on which work has already begun, covers a feasibility study\naimed at assessing the technical, operational, regulatory, financial and\norganisational conditions necessary for the potential launch of a pilot\nscreening programme in the country.\n\nThe study will include operational workflow definition, laboratory and\nlogistics assessment, legal and regulatory review, financial modelling,\nfunding-strategy analysis and an in-country mission by Hospitex\nrepresentatives. At the end of the assignment, Hospitex will deliver an\nOperational Project Document intended to support institutional review and the\npotential structuring of the next phase.\n\nSubject to the positive outcome of the feasibility study and to the completion\nof the required institutional and contractual steps, the parties plan to\nevaluate a first implementation phase for an estimated value of approximately\n€1 million.\n\nUrine24 is the screening model developed by Hospitex International to\nfacilitate the early detection of urinary tract cancers through a modular and\nscalable pathway, adapted for deployment in healthcare systems with varying\nlevels of infrastructure and diagnostic capabilities.\n\nThis collaboration follows an institutional visit to Hospitex’s\nheadquarters, organised as part of the Health Study Tour promoted by the\nItalian Trade Agency (ICE), with the participation of healthcare delegations\nfrom Asian countries.\n\n-----------------------\n\nAbout ALIKO SCIENTIFIC (Ikonisys SA)\n\nHeadquartered in Paris, ALIKO SCIENTIFIC is the parent company of an\ninternational ecosystem of businesses dedicated to advancing oncology\ndiagnostics. Listed on Euronext Growth Paris under the ticker ALIKO, the\ncompany coordinates industrial, financial and research activities through its\nsubsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO\nSCIENTIFIC’s mission is to innovate cancer diagnosis by uniting cutting-edge\ntechnologies, resources, and strategic investments to create a global center\nof excellence in oncology.\n\nFor more information, visit: www.alikoscientific.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.alikoscientific.com&esheet=54575220&newsitemid=20260722811359&lan=en-US&anchor=www.alikoscientific.com&index=1&md5=0f3c61886e4a9cf439a11f51dec92bd0)\n\nAbout IKONISYS\n\nIkonisys is a global leader in automated diagnostics, specializing in\nfluorescence in situ hybridization (FISH) and circulating tumor cell (CTC)\ndetection. Leveraging advanced artificial intelligence (AI) and a fully\nautomated microscopy platform, Ikonisys provides unmatched precision,\nscalability, and efficiency in cancer diagnostics and treatment monitoring.\nRecognized as pioneer in automation for rare cell detection, Ikonisys is at\nthe forefront of personalized medicine, empowering clinicians to deliver\ntargeted therapies and improve patient outcomes.\n\nFor more information, visit: www.ikonisys.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fikonisys.com%2F&esheet=54575220&newsitemid=20260722811359&lan=en-US&anchor=www.ikonisys.com&index=2&md5=35c137c826f1f496dbf1772bf32381ee)\n\nAbout HOSPITEX\n\nHospitex, based in Florence, Italy, is a global leader in cytology innovation.\nThe company conducts in-house research, development, and production, thus\nensuring the highest standards of quality. Hospitex offers the world’s most\nadvanced Liquid-Based Cytology (LBC) technology, capable of processing any\ncytological sample with unmatched precision. Hospitex is uniquely positioned\nas the only company fully prepared for seamless digital integration, paving\nthe way for a transformative future in cytology diagnostics.\n\nFor more information, visit: www.hospitex.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhospitex.com%2F&esheet=54575220&newsitemid=20260722811359&lan=en-US&anchor=www.hospitex.com&index=3&md5=c73f921d73f84be951e719dffcad708b)\n\nDisclaimer\n\nThis press release contains forward-looking statements about the Company’s\nprospects and development. These statements are sometimes identified by the\nuse of the future tense, the conditional tense and forward-looking words such\nas “believe”, “aim to”, “expect”, “intend”, “estimate”,\n“believe”, “should”, “could”, “would” or “will” or, where\nappropriate, the negative of these terms or any other similar variants or\nexpressions. This information is not historical data and should not be\nconstrued as a guarantee that the facts and data set forth will occur. This\ninformation is based on data, assumptions and estimates considered reasonable\nby the Company. It is subject to change or modification due to uncertainties\nrelating to the economic, financial, competitive and regulatory environment.\nThis information contains data relating to the Company’s intentions,\nestimates and objectives concerning, in particular, the market, strategy,\ngrowth, results, financial situation and cash flow of the Company. The\nforward-looking information contained in this press release is made only as of\nthe date of this press release. The Company does not undertake to update any\nforward-looking information contained in this press release, except as\nrequired by applicable law or regulation. The Company operates in a\ncompetitive and rapidly changing environment and therefore cannot anticipate\nall of the risks, uncertainties or other factors that may affect its business,\ntheir potential impact on its business or the extent to which the\nmaterialization of any one risk or combination of risks could cause results to\ndiffer materially from those expressed in any forward-looking information, it\nbeing recalled that none of this forward-looking information constitutes a\nguarantee of actual results.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260722811359/en/\n(https://www.businesswire.com/news/home/20260722811359/en/)\n\nIkonisys \n\nAlessandro Mauri\n\nCFO\n\ninvestors@ikonisys.com (mailto:investors@ikonisys.com)\n\nNewCap \n\nLouis-Victor Delouvrier/Alexandre Massias\n\nInvestor Relations\n\nIkonisys@newcap.eu \n(mailto:ikonisys@newcap.eu) \nTel.: +33 (0)1 44 71 94 94\n\nNewCap \n\nNicolas Mérigeau\n\nMedia Relations\n\nIkonisys@newcap.eu \n(mailto:ikonisys@newcap.eu) \nTel.: +33 (0)1 44 71 94 98\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-07-23T05:30:00.207079013Z","server_sent_at_ms":1784784600207},"received_at":"2026-07-23T05:30:00.338Z","source_url":"https://www.businesswire.com/news/home/20260722811359/en/"},"analysis":{"id":"85119","press_release_id":"96078","analysis_json":{"industry":{"label":"Health Care Equipment","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Aliko Scientific’s subsidiary Hospitex International signed an agreement with the Uzbek Oncology Institute to conduct a feasibility study for a national urinary tract cancer screening program using the Urine24 model.\n\nThe study will assess technical, regulatory, and financial conditions for a potential pilot program, representing a strategic expansion into international markets.\n\nSubject to a positive outcome, the parties plan to evaluate a first implementation phase with an estimated value of approximately €1 million.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Feasibility study signed for national Urine24 screening program in Uzbekistan."},"keyFigures":{"customDimensions":{"potential_implementation_value":"€1 million"}},"quotedText":"This first agreement confirms the growing international interest in Urine24 and represents a significant recognition of Aliko Scientific’s expertise in the field of large-scale oncological diagnostic solutions.","namedEntities":{"people":[{"name":"Francesco Trisolini","role":"Managing Director of Hospitex International"}],"products":["Urine24"],"companies":[{"name":"Aliko Scientific SA","ticker":"ALIKO"},{"name":"Hospitex International S.r.l.","relationship":"subsidiary"},{"name":"Jizzakh branch of the Republican Scientific and Practical Centre specialising in oncology and radiology","relationship":"partner"},{"name":"Italian Trade Agency (ICE)","relationship":"organization"},{"name":"Ikonisys Inc.","relationship":"subsidiary"}],"dollarAmounts":[{"amount":"€1 million","context":"estimated value of first implementation phase"}]},"materialImpact":{"score":2,"reasoning":"Feasibility study signed for a national screening program in Uzbekistan, validating the Urine24 model internationally. While strategically positive, the immediate financial impact is limited and the potential implementation phase (~€1M) is contingent on study results."},"tickerRelevance":{"others":[],"primary":"ALIKO"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":["partnership"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"operational-milestone","geographicReach":"single-country"}},"event_type":"operations_update","event_type_secondary":["partnership"],"sentiment":"bullish","material_impact_score":2,"narrative":"Aliko Scientific’s subsidiary Hospitex International signed an agreement with the Uzbek Oncology Institute to conduct a feasibility study for a national urinary tract cancer screening program using the Urine24 model.\n\nThe study will assess technical, regulatory, and financial conditions for a potential pilot program, representing a strategic expansion into international markets.\n\nSubject to a positive outcome, the parties plan to evaluate a first implementation phase with an estimated value of approximately €1 million.","key_figures":{"customDimensions":{"potential_implementation_value":"€1 million"}},"named_entities":{"people":[{"name":"Francesco Trisolini","role":"Managing Director of Hospitex International"}],"products":["Urine24"],"companies":[{"name":"Aliko Scientific SA","ticker":"ALIKO"},{"name":"Hospitex International S.r.l.","relationship":"subsidiary"},{"name":"Jizzakh branch of the Republican Scientific and Practical Centre specialising in oncology and radiology","relationship":"partner"},{"name":"Italian Trade Agency (ICE)","relationship":"organization"},{"name":"Ikonisys Inc.","relationship":"subsidiary"}],"dollarAmounts":[{"amount":"€1 million","context":"estimated value of first implementation phase"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-23T05:32:00.607Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"operational-milestone","geographicReach":"single-country"}},"durationMs":120262,"modelName":"glm-4.7"}}